Malveiro Carla, Boavida Sofia, Cargaleiro Catarina, Bernardino Ana V, Correia Inês R, Reis Cátia, Matos Leonor, Sardinha Luís B, Cardoso Maria João, Saint-Maurice Pedro F
Champalimaud Foundation, Lisbon, Portugal.
Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Cruz-Quebrada, Portugal.
Sci Rep. 2025 Jul 11;15(1):25075. doi: 10.1038/s41598-025-99208-0.
Breast cancer is the most diagnosed cancer in women worldwide and its treatment often leads to the onset of sleep disturbances. While much research has focused on chemotherapy's impact on overall sleep quality through subjective measures, less attention has been given to its effects on specific sleep metrics such as duration, timing, continuity, and naps. This preliminary study addresses this gap by assessing sleep duration, timing, and regularity, using the Emfit QS device over 100 consecutive days in 24 breast cancer patients undergoing neoadjuvant chemotherapy. Additionally, we incorporated the Pittsburgh Sleep Quality Index (PSQI) to measure reported sleep quality. Our results suggest that chemotherapy may influence the duration for time spent in bed (ptrend = 0.02) measured by the Emfit QS. Duration in bed decreased over the first seven weeks (e.g., 9.3 h/day at week 1 vs. 8.5 h/day at week 8), and increased thereafter to similar amounts as those recorded in week 1 (9.0 h/day at week 15). Sleep timing and regularity, also measured by the Emfit QS, remained unchanged. Overall sleep quality, as measured by the PSQI, did not change over time. However, our analysis of the individual components of the PSQI revealed that sleep disturbances increased as treatment progressed from week 1 to week 8 (1.3 ± 0.6 to 1.7 ± 0.6; p = 0.01), concurrently with an increase in insomnia symptoms. Approximately, 33%, 63%, and 73% reported having insomnia symptoms at week 1, 8, and 15. These findings highlight critical periods during treatment when patients are vulnerable to disrupted sleep. Future research should focus on interventions to mitigate sleep disturbances, improving patient well-being and overall quality of life.
乳腺癌是全球女性中诊断出最多的癌症，其治疗常常会导致睡眠障碍的出现。虽然许多研究通过主观测量方法关注化疗对整体睡眠质量的影响，但对其对特定睡眠指标（如持续时间、时间安排、连续性和小睡）的影响关注较少。这项初步研究通过使用Emfit QS设备，对24名接受新辅助化疗的乳腺癌患者连续100天评估睡眠持续时间、时间安排和规律性，填补了这一空白。此外，我们纳入了匹兹堡睡眠质量指数（PSQI）来测量报告的睡眠质量。我们的结果表明，化疗可能会影响Emfit QS测量的卧床时间（ptrend = 0.02）。卧床时间在前七周减少（例如，第1周为9.3小时/天，第8周为8.5小时/天），此后增加到与第1周记录的时间相似（第15周为9.0小时/天）。同样由Emfit QS测量的睡眠时间安排和规律性保持不变。通过PSQI测量的整体睡眠质量随时间没有变化。然而，我们对PSQI各个组成部分的分析显示，随着治疗从第1周进展到第8周，睡眠障碍增加（从1.3±0.6增加到1.7±0.6；p = 0.01），同时失眠症状也增加。大约33%、63%和73%的患者在第1周、第8周和第15周报告有失眠症状。这些发现突出了治疗期间患者易受睡眠干扰的关键时期。未来的研究应侧重于减轻睡眠障碍的干预措施，以改善患者的幸福感和整体生活质量。
